Kairos Pharma to Host KOL Event Discussing Promising Interim Efficacy Results of ENV105 in Advanced Prostate Cancer Trial

Reuters

2025/09/11

<a href="https://laohu8.com/S/KAPA">Kairos Pharma</a> to Host KOL Event Discussing Promising Interim Efficacy Results of ENV105 in Advanced Prostate Cancer Trial

Kairos Pharma Ltd. has announced a forthcoming virtual Key Opinion Leader $(KOL)$ event to discuss the interim efficacy results of its Phase 2 trial for ENV105, a first-in-class CD105 antagonist, in treating advanced prostate cancer. The event is scheduled for September 18th and will feature perspectives from principal investigators involved in the trial. The interim safety analysis reported in July indicated that ENV105 was well tolerated when combined with standard hormone therapy, apalutamide, in the initial 10 patients, with no dose-limiting toxicities or unexpected adverse events observed. Participants can register to receive access to the webcast, where experts including Dr. Neil Bhowmick, Dr. Umang Swami, Dr. Richard Lee, and Dr. Edwin Posadas will provide insights on the trial results and the potential role of ENV105 in addressing cancer drug resistance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250911712367) on September 11, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2566998286"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2566998286\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2566998286?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-11 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566998286","market":"nz","top_or_hot":-1,"title":"Kairos Pharma to Host KOL Event Discussing Promising Interim Efficacy Results of ENV105 in Advanced Prostate Cancer Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/KAPA\">Kairos Pharma</a> to Host KOL Event Discussing Promising Interim Efficacy Results of ENV105 in Advanced Prostate Cancer Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Kairos Pharma Ltd. has announced a forthcoming virtual Key Opinion Leader <a href=\"https://laohu8.com/S/KOL\">$(KOL)$</a> event to discuss the interim efficacy results of its Phase 2 trial for ENV105, a first-in-class CD105 antagonist, in treating advanced prostate cancer. The event is scheduled for September 18th and will feature perspectives from principal investigators involved in the trial. The interim safety analysis reported in July indicated that ENV105 was well tolerated when combined with standard hormone therapy, apalutamide, in the initial 10 patients, with no dose-limiting toxicities or unexpected adverse events observed. Participants can register to receive access to the webcast, where experts including Dr. Neil Bhowmick, Dr. Umang Swami, Dr. Richard Lee, and Dr. Edwin Posadas will provide insights on the trial results and the potential role of ENV105 in addressing cancer drug resistance.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250911712367) on September 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kairos Pharma to Host KOL Event Discussing Promising Interim Efficacy Results of ENV105 in Advanced Prostate Cancer Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKairos Pharma to Host KOL Event Discussing Promising Interim Efficacy Results of ENV105 in Advanced Prostate Cancer Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-11 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/KAPA\">Kairos Pharma</a> to Host KOL Event Discussing Promising Interim Efficacy Results of ENV105 in Advanced Prostate Cancer Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Kairos Pharma Ltd. has announced a forthcoming virtual Key Opinion Leader <a href=\"https://laohu8.com/S/KOL\">$(KOL)$</a> event to discuss the interim efficacy results of its Phase 2 trial for ENV105, a first-in-class CD105 antagonist, in treating advanced prostate cancer. The event is scheduled for September 18th and will feature perspectives from principal investigators involved in the trial. The interim safety analysis reported in July indicated that ENV105 was well tolerated when combined with standard hormone therapy, apalutamide, in the initial 10 patients, with no dose-limiting toxicities or unexpected adverse events observed. Participants can register to receive access to the webcast, where experts including Dr. Neil Bhowmick, Dr. Umang Swami, Dr. Richard Lee, and Dr. Edwin Posadas will provide insights on the trial results and the potential role of ENV105 in addressing cancer drug resistance.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250911712367) on September 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KAPA","symbol_name":"Kairos Pharma, Ltd.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250911:nNDL9njcbp:1","article_id":"2566998286","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566998286","pubTimestamp":1757592032,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Kairos Pharma Ltd. has announced a forthcoming virtual Key Opinion Leader  event to discuss the interim efficacy results of its Phase 2 trial for ENV105, a first-in-class CD105 antagonist, in treating advanced prostate cancer. The event is scheduled for September 18th and will feature perspectives from principal investigators involved in the trial. The interim safety analysis reported in July indicated that ENV105 was well tolerated when combined with standard hormone therapy, apalutamide, in the initial 10 patients, with no dose-limiting toxicities or unexpected adverse events observed. Participants can register to receive access to the webcast, where experts including Dr. Neil Bhowmick, Dr. Umang Swami, Dr. Richard Lee, and Dr. Edwin Posadas will provide insights on the trial results and the potential role of ENV105 in addressing cancer drug resistance.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KAPA":"Kairos Pharma, Ltd.","BK4139":"生物科技"},"translate_title":"Kairos Pharma将举办KOL活动，讨论ENV105在晚期前列腺癌试验中有希望的中期疗效结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KAPA":0.9},"content_text":"Kairos Pharma to Host KOL Event Discussing Promising Interim Efficacy Results of ENV105 in Advanced Prostate Cancer Trial\n    \n\n        Kairos Pharma Ltd. has announced a forthcoming virtual Key Opinion Leader $(KOL)$ event to discuss the interim efficacy results of its Phase 2 trial for ENV105, a first-in-class CD105 antagonist, in treating advanced prostate cancer. The event is scheduled for September 18th and will feature perspectives from principal investigators involved in the trial. The interim safety analysis reported in July indicated that ENV105 was well tolerated when combined with standard hormone therapy, apalutamide, in the initial 10 patients, with no dose-limiting toxicities or unexpected adverse events observed. Participants can register to receive access to the webcast, where experts including Dr. Neil Bhowmick, Dr. Umang Swami, Dr. Richard Lee, and Dr. Edwin Posadas will provide insights on the trial results and the potential role of ENV105 in addressing cancer drug resistance.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250911712367) on September 11, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}